Matrix metalloproteinases (MMPs) in health and disease: an overview

被引:564
作者
Malemud, CJ
机构
[1] Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Dept Med, Div Rheumat Dis, Cleveland, OH 44106 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2006年 / 11卷
关键词
matrix metalloproteinase; protein kinase; gene transcription; TIMP; growth plate; cardiovascular; arthritis; cancer; cerebral ischemia;
D O I
10.2741/1915
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases ( MMPs) are members of an enzyme family that require a zinc ion in their active site for catalytic activity. MMPs are critical for maintaining tissue allostasis. MMPs are active at neutral pH and can therefore catalyze the normal turnover of extracellular matrix (ECM) macromolecules such as the interstitial and basement membrane collagens, proteoglycans such as aggrecan, decorin, biglycan, fibromodulin and versican as well as accessory ECM proteins such as fibronectin. Members of the MMP family include the "classical" MMPs, the membrane-bound MMPs (MT-MMPs) the ADAMs (a disintegrin and metalloproteinase; adamlysins) and the ADAMTS ( a disintegrin and metalloproteinase with thrombospondin motif). There are more than 20 members in the MMP and ADAMTS family including the collagenases, gelatinases, stromelysins, some elastases and aggrecanases. Adamlysins are membrane-bound MMPs that also degrade aggrecan, but more importantly, one ADAM family member (i.e. ADAM-17) is a tumor necrosis actor-alpha (TNF-alpha)-converting enzyme (TACE) that activates pro-TNF-alpha. Most of the MMPs are synthesized as inactive latent enzymes. Conversion to the active enzyme is generally mediated by activator systems that include plasminogen activator or the pro-hormone convertase, furin. MMP activity is regulated by a group of endogenous proteins, called, tissue inhibitor of metalloproteinases (TIMPs) that bind to active and alternative sites of the activated MMP. Significant advances have occurred in the understanding of the regulation of MMPs, ADAMs and ADAMTSs gene expression. In addition, development of MMP inhibitors to study MMP structure/function relationships spawned many studies to determine the effectiveness of MMP inhibitors in regulating abnormal connective tissue turnover. In addition, development of MMP null mice carrying specific MMP deletions has provided an opportunity to explore the role of MMPs in normal development as well as in such diverse conditions and diseases as skeletal dysplasias, coronary artery and heart disease, arthritis, cancer, and brain disorders.
引用
收藏
页码:1696 / 1701
页数:6
相关论文
共 50 条
[1]   Timeline - Matrix metalloproteinases: a tail of a frog that became a prince [J].
Brinckerhoff, CE ;
Matrisian, LM .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (03) :207-214
[2]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[3]   Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells [J].
Crawford, HC ;
Matrisian, LM .
ENZYME & PROTEIN, 1996, 49 (1-3) :20-37
[4]   Multiple roles for MMPs and TIMPs in cerebral ischemia [J].
Cunningham, LA ;
Wetzel, M ;
Rosenberg, GA .
GLIA, 2005, 50 (04) :329-339
[5]  
Danielsen CC, 1998, J MOL CELL CARDIOL, V30, P1431
[6]   Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects [J].
Fingleton, B .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (03) :385-397
[7]   Endogenous angiogenesis inhibitors [J].
Folkman, J .
APMIS, 2004, 112 (7-8) :496-507
[8]   INCREASED EXPRESSION OF MATRIX METALLOPROTEINASES AND MATRIX-DEGRADING ACTIVITY IN VULNERABLE REGIONS OF HUMAN ATHEROSCLEROTIC PLAQUES [J].
GALIS, ZS ;
SUKHOVA, GK ;
LARK, MW ;
LIBBY, P .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (06) :2493-2503
[9]   Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice [J].
Glasson, SS ;
Askew, R ;
Sheppard, B ;
Carito, BA ;
Blanchet, T ;
Ma, HL ;
Flannery, CR ;
Kanki, K ;
Wang, E ;
Peluso, D ;
Yang, ZY ;
Majumdar, MK ;
Morris, EA .
ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2547-2558
[10]   Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis [J].
Glasson, SS ;
Askew, R ;
Sheppard, B ;
Carito, B ;
Blanchet, T ;
Ma, HL ;
Flannery, CR ;
Peluso, D ;
Kanki, K ;
Yang, ZY ;
Majumdar, MK ;
Morris, EA .
NATURE, 2005, 434 (7033) :644-648